395 related articles for article (PubMed ID: 21888261)
1. Treatment of immunoglobulin light chain (primary or AL) amyloidosis.
Gertz MA; Buadi FK; Hayman SR
Oncology (Williston Park); 2011 Jun; 25(7):620-6. PubMed ID: 21888261
[TBL] [Abstract][Full Text] [Related]
2. New and developing therapies for AL amyloidosis.
Zumbo G; Sadeghi-Alavijeh O; Hawkins PN; Fontana M
Expert Opin Pharmacother; 2017 Feb; 18(2):139-149. PubMed ID: 28002971
[TBL] [Abstract][Full Text] [Related]
3. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis.
Comenzo RL
Contrib Nephrol; 2007; 153():195-210. PubMed ID: 17075231
[TBL] [Abstract][Full Text] [Related]
4. High-dose melphalan with autologous stem cell transplantation after VAD induction chemotherapy for treatment of amyloid light chain amyloidosis: a single centre prospective phase II study.
Perz JB; Schonland SO; Hundemer M; Kristen AV; Dengler TJ; Zeier M; Linke RP; Ho AD; Goldschmidt H
Br J Haematol; 2004 Dec; 127(5):543-51. PubMed ID: 15566357
[TBL] [Abstract][Full Text] [Related]
5. How we treat systemic light-chain amyloidosis.
Chaulagain CP; Comenzo RL
Clin Adv Hematol Oncol; 2015 May; 13(5):315-24. PubMed ID: 26352777
[TBL] [Abstract][Full Text] [Related]
6. Regression of cardiac wall thickness following chemotherapy and stem cell transplantation for light chain (AL) amyloidosis.
Meier-Ewert HK; Sanchorawala V; Berk J; Finn KT; Skinner M; Seldin DC; Ruberg FL
Amyloid; 2011 Jun; 18 Suppl 1():130-1. PubMed ID: 21838460
[No Abstract] [Full Text] [Related]
7. Who knows how to treat systemic light chain amyloidosis?
Comenzo RL
Oncology (Williston Park); 2011 Jun; 25(7):626, 628-9, 632-3. PubMed ID: 21888262
[No Abstract] [Full Text] [Related]
8. Indications for high-dose chemotherapy with autologous stem cell support in patients with systemic amyloid light chain amyloidosis.
Schonland SO; Perz JB; Hundemer M; Hegenbart U; Kristen AV; Hund E; Dengler TJ; Beimler J; Zeier M; Singer R; Linke RP; Ho AD; Goldschmidt H
Transplantation; 2005 Sep; 80(1 Suppl):S160-3. PubMed ID: 16286897
[TBL] [Abstract][Full Text] [Related]
9. Recent advances in the management of AL Amyloidosis.
Kastritis E; Dimopoulos MA
Br J Haematol; 2016 Jan; 172(2):170-86. PubMed ID: 26491974
[TBL] [Abstract][Full Text] [Related]
10. Immunoglobulin light chain amyloidosis: 2014 update on diagnosis, prognosis, and treatment.
Gertz MA
Am J Hematol; 2014 Dec; 89(12):1132-40. PubMed ID: 25407896
[TBL] [Abstract][Full Text] [Related]
11. [Renal disorders associated with monoclonal gammopathies: diagnostic and therapeutic progress].
Bridoux F; Delbes S; Sirac C; Pourreau F; Puyade M; Desport E; Jaccard A; Fermand JP; Touchard G
Presse Med; 2012 Mar; 41(3 Pt 1):276-89. PubMed ID: 22244725
[TBL] [Abstract][Full Text] [Related]
12. Stem cell transplantation for immunoglobulin light chain amyloidosis.
Sher T; Gertz MA
Curr Probl Cancer; 2017; 41(2):129-137. PubMed ID: 28457657
[TBL] [Abstract][Full Text] [Related]
13. Evolution of Hematopoietic Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Sher T; Dispenzieri A; Gertz MA
Biol Blood Marrow Transplant; 2016 May; 22(5):796-801. PubMed ID: 26475727
[TBL] [Abstract][Full Text] [Related]
14. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
[TBL] [Abstract][Full Text] [Related]
15. Immunoglobulin light chain amyloidosis.
Merlini G; Comenzo RL; Seldin DC; Wechalekar A; Gertz MA
Expert Rev Hematol; 2014 Feb; 7(1):143-56. PubMed ID: 24350907
[TBL] [Abstract][Full Text] [Related]
16. Immunoglobulin Light-Chain Amyloidosis: From Basics to New Developments in Diagnosis, Prognosis and Therapy.
Muchtar E; Buadi FK; Dispenzieri A; Gertz MA
Acta Haematol; 2016; 135(3):172-90. PubMed ID: 26771835
[TBL] [Abstract][Full Text] [Related]
17. Emerging Advances in the Management of Cardiac Amyloidosis.
Vranian MN; Sperry BW; Valent J; Hanna M
Curr Cardiol Rep; 2015 Nov; 17(11):100. PubMed ID: 26374453
[TBL] [Abstract][Full Text] [Related]
18. High dose melphalan and autologous peripheral blood stem cell transplantation in AL amyloidosis.
Sanchorawala V
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1131-44. PubMed ID: 25459183
[TBL] [Abstract][Full Text] [Related]
19. Osteopontin: a novel predictor of survival in patients with systemic light-chain amyloidosis.
Kristen AV; Rosenberg M; Lindenmaier D; Merkle C; Steen H; Andre F; Schönland SO; Schnabel PA; Schuster T; Röcken C; Giannitsis E; Katus HA; Frey N
Amyloid; 2014 Sep; 21(3):202-10. PubMed ID: 25007036
[TBL] [Abstract][Full Text] [Related]
20. Treatment of primary systemic amyloidosis (AL): role of intensive and standard therapy.
Sher T; Hayman SR; Gertz MA
Clin Adv Hematol Oncol; 2012 Oct; 10(10):644-51. PubMed ID: 23187770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
